Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.

The first-line liver cancer Emerald-1 trial is positive, but only up to a point.

The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.

The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.

Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.

After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.